Optimized 1,4-oxazine BACE1 inhibitor shows improved safety profile in preclinical studies Sep. 10, 2018
Checkpoint Therapeutics reports promising phase I/II data with CK-101 in EGFR-mutated NSCLC Sep. 7, 2018